VIM and prostate cancer: Furthermore, the relative phosphorylation of eEF2 at T56 in DU145 prostate cancer cells was less affected by treatment of TGF-β1 even in the presence of CQ and consequently Vimentin was similarly expressed in response to TGF-β1 (Figure 4).